Scholarlink

<p>This multicenter, parallel-arm, superiority, randomized, double-blind, placebo-controlled study evaluates the efficacy of Totum-63 (T63), a polyphenol-rich blend of plant extracts, in improving fasting plasma glucose (FPG) in individuals with prediabetes or early-stage type 2 diabetes (T2D). Individuals from seven European countries with FPG between 110-220 mg/dL were randomized to receive placebo (PBO, n = 210), T63 (5 g/d) distributed thrice daily (T63 TID, n = 212) or twice daily (T63 BID, open-label arm, n = 214) over six months. Individuals were randomly assigned using a dynamic randomization algorithm, stratified by their glycemic status at baseline (FPG &lt; 126 mg/dL or FPG ≥ 126) and the investigational site country. The primary outcome was the FPG change in T63 TID compared to PBO in the intention-to-treat population. Secondary assessments included changes in diabetes biomarkers, lipid profile, anthropometric measurements and subpopulation analyses based on glycemic status. During the whole study, neither the investigators nor the subjects were aware of the product they tested, except in the open arm. After six months, FPG was significantly reduced in the T63 TID group (PBO-adjusted mixed model estimated difference, PBO-AD = −3.8 mg/dL, 95% CI: [−5.9; −1.7], p = 0.0149) and the T63 BID group (PBO-AD = −5.5 mg/dL, 95% CI: [−9.7; −1.3] p &lt; 0.001). Hence, T63 may represent a non-pharmaceutical strategy for T2D prevention. ClinicalTrials.gov Identifier: NCT04423302. Funding: This trial was funded by Valbiotis®.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Totum-63, a plant-based polyphenol-rich extract, in prediabetes or early-stage type 2 diabetes: an international, multicenter, randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Vivien Chavanelle,
  • Yolanda F. Otero,
  • Murielle Fayat Cazaubiel,
  • Jean-Marie Bard,
  • Bruno Pereira,
  • Véronique Sapone,
  • Annie Bouchard-Mercier,
  • Maxime Bargetto,
  • Nathalie Boisseau,
  • Bruno Guigas,
  • Sébastien Peltier,
  • Florian Le Joubioux,
  • Thierry Maugard,
  • Samy Hadjadj,
  • Pascal Sirvent,
  • André Marette

摘要

This multicenter, parallel-arm, superiority, randomized, double-blind, placebo-controlled study evaluates the efficacy of Totum-63 (T63), a polyphenol-rich blend of plant extracts, in improving fasting plasma glucose (FPG) in individuals with prediabetes or early-stage type 2 diabetes (T2D). Individuals from seven European countries with FPG between 110-220 mg/dL were randomized to receive placebo (PBO, n = 210), T63 (5 g/d) distributed thrice daily (T63 TID, n = 212) or twice daily (T63 BID, open-label arm, n = 214) over six months. Individuals were randomly assigned using a dynamic randomization algorithm, stratified by their glycemic status at baseline (FPG < 126 mg/dL or FPG ≥ 126) and the investigational site country. The primary outcome was the FPG change in T63 TID compared to PBO in the intention-to-treat population. Secondary assessments included changes in diabetes biomarkers, lipid profile, anthropometric measurements and subpopulation analyses based on glycemic status. During the whole study, neither the investigators nor the subjects were aware of the product they tested, except in the open arm. After six months, FPG was significantly reduced in the T63 TID group (PBO-adjusted mixed model estimated difference, PBO-AD = −3.8 mg/dL, 95% CI: [−5.9; −1.7], p = 0.0149) and the T63 BID group (PBO-AD = −5.5 mg/dL, 95% CI: [−9.7; −1.3] p < 0.001). Hence, T63 may represent a non-pharmaceutical strategy for T2D prevention. ClinicalTrials.gov Identifier: NCT04423302. Funding: This trial was funded by Valbiotis®.